vs
Ascendis Pharma A/S（ASND）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
Ascendis Pharma A/S的季度营收约是ROGERS CORP的1.3倍（$267.3M vs $200.5M），Ascendis Pharma A/S同比增速更快（42.3% vs 5.2%），过去两年Ascendis Pharma A/S的营收复合增速更高（60.7% vs -3.3%）
Ascendis Pharma A/S是一家聚焦内分泌疾病治疗领域的生物制药企业，核心业务覆盖生长激素疗法的研发、生产与商业化。其依托重组DNA技术生产的生长激素类处方药物，可用于治疗多种生长激素缺乏相关适应症，临床应用场景广泛。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
ASND vs ROG — 直观对比
营收规模更大
ASND
是对方的1.3倍
$200.5M
营收增速更快
ASND
高出37.1%
5.2%
两年增速更快
ASND
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $267.3M | $200.5M |
| 净利润 | — | $4.5M |
| 毛利率 | 90.5% | 32.2% |
| 营业利润率 | — | — |
| 净利率 | — | 2.2% |
| 营收同比 | 42.3% | 5.2% |
| 净利润同比 | — | 421.4% |
| 每股收益（稀释后） | — | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASNDROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $267.3M | $201.5M | ||
| Q3 25 | $230.7M | $216.0M | ||
| Q2 25 | $170.7M | $202.8M | ||
| Q1 25 | $109.0M | $190.5M | ||
| Q4 24 | $187.8M | $192.2M | ||
| Q3 24 | $62.5M | $210.3M | ||
| Q2 24 | $38.9M | $214.2M |
净利润ASNDROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | — | $4.6M | ||
| Q3 25 | $-65.9M | $8.6M | ||
| Q2 25 | $-42.0M | $-73.6M | ||
| Q1 25 | $-102.2M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | $-107.1M | $10.7M | ||
| Q2 24 | $-118.1M | $8.1M |
毛利率ASNDROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 90.5% | 31.5% | ||
| Q3 25 | 89.5% | 33.5% | ||
| Q2 25 | 80.1% | 31.6% | ||
| Q1 25 | 82.6% | 29.9% | ||
| Q4 24 | 91.9% | 32.1% | ||
| Q3 24 | 80.6% | 35.2% | ||
| Q2 24 | 68.2% | 34.1% |
营业利润率ASNDROG
| Q1 26 | — | — | ||
| Q4 25 | — | 3.5% | ||
| Q3 25 | 5.1% | 7.3% | ||
| Q2 25 | -33.5% | -33.3% | ||
| Q1 25 | -103.2% | -0.2% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | -167.3% | 6.9% | ||
| Q2 24 | -370.2% | 5.3% |
净利率ASNDROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | -28.5% | 4.0% | ||
| Q2 25 | -24.6% | -36.3% | ||
| Q1 25 | -93.7% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | -171.5% | 5.1% | ||
| Q2 24 | -303.9% | 3.8% |
每股收益（稀释后）ASNDROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | — | $0.20 | ||
| Q3 25 | — | $0.48 | ||
| Q2 25 | — | $-4.00 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | — | $-0.04 | ||
| Q3 24 | — | $0.58 | ||
| Q2 24 | — | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $665.3M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-175.8M | $1.2B |
| 总资产 | $1.4B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASNDROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $665.3M | $197.0M | ||
| Q3 25 | $582.2M | $167.8M | ||
| Q2 25 | $533.6M | $157.2M | ||
| Q1 25 | $559.4M | $175.6M | ||
| Q4 24 | $604.3M | $159.8M | ||
| Q3 24 | $675.6M | $146.4M | ||
| Q2 24 | $279.4M | $119.9M |
股东权益ASNDROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-175.8M | $1.2B | ||
| Q3 25 | $-188.0M | $1.2B | ||
| Q2 25 | $-202.6M | $1.2B | ||
| Q1 25 | $-205.0M | $1.3B | ||
| Q4 24 | $-114.2M | $1.3B | ||
| Q3 24 | $-105.1M | $1.3B | ||
| Q2 24 | $-346.8M | $1.3B |
总资产ASNDROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.4B | $1.4B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $819.0M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $58.2M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | — | $1.1M |
| 自由现金流率自由现金流/营收 | — | 0.5% |
| 资本支出强度资本支出/营收 | — | 2.3% |
| 现金转化率经营现金流/净利润 | — | 1.29× |
| 过去12个月自由现金流最近4个季度 | — | $70.1M |
8季度趋势，按日历期对齐
经营现金流ASNDROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $58.2M | $46.9M | ||
| Q3 25 | — | $28.9M | ||
| Q2 25 | — | $13.7M | ||
| Q1 25 | $-15.5M | $11.7M | ||
| Q4 24 | $-330.7M | $33.7M | ||
| Q3 24 | — | $42.4M | ||
| Q2 24 | — | $22.9M |
自由现金流ASNDROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | — | $42.2M | ||
| Q3 25 | — | $21.2M | ||
| Q2 25 | — | $5.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | — | $25.2M | ||
| Q2 24 | — | $8.8M |
自由现金流率ASNDROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | — | 20.9% | ||
| Q3 25 | — | 9.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 12.0% | ||
| Q2 24 | — | 4.1% |
资本支出强度ASNDROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 8.2% | ||
| Q2 24 | — | 6.6% |
现金转化率ASNDROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
